CTOs on the Move


 
BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bpgbio.com
  • 500 Old Connecticut Path
    Framingham, MA USA 01701
  • Phone: 617.588.0083

Executives

Name Title Contact Details

Similar Companies

Abengoa

Abengoa applies innovative technology solutions for sustainability in the energy and environment sectors, generating electricity from renewable resources, converting biomass into biofuels and producing drinking water from sea water. Abengoa’s business is structured around three activities.

Telik

Telik is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

Tarveda Therapeutics

Tarveda Therapeutics is a clinical stage biopharmaceutical company that takes a novel approach to cancer treatment by creating proprietary Pentarins, which are potent and selective, miniaturized conjugates uniquely designed to drive efficacy through deep and rapid penetration into solid tumors resulting in sustained payload accumulation and cancer cell death. Through our Pentarin platform, we are developing therapeutics to address the limitations of current cancer therapies in solid tumors.

Cue

Our mission is to create tools that empower physicians and consumers by increasing their access to actionable data.